The design of chemical structuresf or medicinal applications, particularly small molecules that are intended to be orally bioavailable, selective,h ave low toxicity and are efficacious is am ultivariate problem. In order to optimise these properties within the constraints of the available chemistry,a nd also to includek nowledge of what makes compounds drug-like, the medicinal chemist has to optimise the problemi nm ultivariate physico-chemicala nd biological spacet of ind an optimals olution. Therea re am ultitude of software algorithmst hat can assist in this process. When combined with in-vitro assays and in-vivo assays, these can assist in the optimisation of putative drug candidates hence complementing the intellectual input of the medicinal chemist.
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The processfrom identifying adiseasetarget to amarketed small molecule product is complex and expensive. Drugs fail due to many factors including al ack of efficacy in the clinic, poor pharmacokinetics and toxicity.U sing computational approaches early in the process can increase the chances of success. It should be noted that decisions on whichs mall moleculec andidatest od evelop are typically taken at an early stage in the development process;t he lead molecule becomes more and more difficult to change as investment increases, thereforet oa void costly expense, it is best to invest in early stage assessment using computational, in-vitro and in-vivo assessment, including human tissues, if available.
Before embarking on ad rug discovery project, experience shows that careful consideration of the viability of the target is of the utmost importance -i si td rugable? Currently most drugst ypically fail due to al ack of efficacy in the clinic. This initial step is probablyt he most important in drug discovery -ideally, the target should be demonstrated to be of relevance in human clinical studies. Unfortunately, it is still the case that am ajor reason for failure of drug discovery projects whicha re based on non-phenotypic endpoints (e.g. molecular biology hypotheses which identify probable novel targets) or in-vivoa nimal models (which show species differences) are later shown to be irrelevant to the human disease process. In addition, we should consider:
* Is there am edical need -P atient population, current therapiesi neffective, toxicity,cost * Is an effective therapy already available -F irst to market is always best -I st he current therapy out of patent, and thereforei nexpensive * Can you be first to market? -D rug discovery is very competitive (how many statins are there?) * Is it commercially viable -I nvestment requiresr eturns! Of course,a savalid academic investigation, we may simply be very interested in the chemistry and biologyo f the target or system,w hich may lead to new and exciting therapeutico pportunitiest hat are discovered by the use of novel pharmacological probes of disease processes.
The basic scientific problem of course is optimising the effect of the putative drug (be it e.g. binding affinity,a llosteric effects, interference with specific biochemical pathways etc.) and obtaining the desired efficacy at af unctional level at the desired target in-vivo,f ollowed by (or best practice is in parallel with) consideration of selectivity and ADME (Absorption,D istribution, Metabolism and Excretion).
Abstract:E arly phase drug discovery is am ulti-parameter optimisation process. Finding drugable targets, discovering starting points for lead optimisation and creating novel structures with new biological properties within these constraints is challenging. As an example of ad rug optimisation strategy, recent work on 5-HT1B antagonists will be described. This is put in the context of the drugability of the target, the desired physicochemical properties of the desired molecules and approaches to compound design to create high affinity,s elective molecules that are optimised to have low Central NervousS ystem (CNS) penetration. As an example, we are currently working to optimise as eries of 5-HT1B antagonists for the treatment of Pulmonary Arterial Hypertension (PAH). 5-HT1B is aG -protein Coupled Receptor( GPCR) of family A, which binds the natural hormone 5-hydroxytryptamine (5-HT). PAHi sc haracterized by vasoconstriction and vascular remodelling of pulmonary arteries and this leadst oaprogressive increase in pulmonary arterial pressure and rightv entricular failure, leading to death, sometimes at an early age. Numerous studies haved emonstrated that 5-HT is involved with the disease process of PAH. 5-HT (also called serotonin) is ap otent vasoconstrictor in pulmonary vessels (including the lung) and also promotes proliferation of smooth muscle cells and hypertrophy.P atients with PAHh ave increased plasmal evels of 5-HT,r esulting from reduced 5-HT re-uptake (hence the interest in the Serotonin Transporter as ad rug targetf or PAH). Importantly,t he appetite-supressing drugs fenfluraminea nd aminorex -w hich enhance 5-HT release by plateletsw hile inhibiting 5-HT uptake are seen to contribute to pulmonary hypertension. Mechanistically,5 -HT released by plateleta ccumulationi nb lood vessels of the lung and the coronary arteries induces vasoconstriction and proliferation, contributing to symptoms. The receptor target we are interested in, 5-HT1B, is expressed in the lung and the coronary arteriesa nd induces vasoconstriction in these arteries. This evidences uggests this target would be relevant for PAHa nd that as ilent, selectivea ntagonist for 5-HT1B would be an excellent probe of the therapeutic utility of thisa pproach. [1] This project is ac ontinuation of our long-standing interest in serotonin (5-hydroxytriptamine) and its effects in health and disease.
5-HT1B is ad rugable target:
* Molecules can be designedt ob ind to the receptor with the desired properties of affinity,p otency and ADME. There are good starting points for synthesis and medicinal chemistry. * 5-HT1B agonists are the top selling prescription medicines for migraine. Sumatriptan and zolmitriptan have accumulated sales of > $6 Billion each * Other drugs target the 5-HT family including e.g. mirtazapine (Zispin, Organon) antidepressant, buspirone (Buspar,B MS) anxiety,p izotifen (Sanomigran,N ovartis) cluster headaches etc.,l ocaserin (Arena), agomelatine (Phase III, Novartis)d epression.
As af irst step, we have defined the desirable characteristics of as uccessful compound for pre-clinical studies. This is important to measure progress and should be the initial step in all drug discovery projects. Here is ab rief summary of adesirable 5-HT1B antagonist profile as an example:
Orally bioavailable 5-HT1B neutral antagonist (main target) with:
* The affinity for the target (5-HT1B) should be better than 20 nM and haveg reater than 20-fold selectivity over otherr eceptors (particularly 5-HT2A) and should also show low affinity againstascreening panel of (80 selected) additional receptors at ac oncentration of 5 mM * Solubility > 30 mg/ml, logD < 1.0, PolarS urfaceA rea (PSA) > 90.0 2 (to reduce Central NervousS ystem (CNS) penetration) * Pharmacokinetic half life > 6hours and ap harmacodynamic half-life compatible with daily or twice daily dosing (pharmcokinetics, PK) * Oral bioavailability of > 30 %, clearance < 35 ml/min/kg with ar educed susceptibility to metabolism,a na cceptable volume of distribution and inactive human metabolites (bioavailability,m etabolism) * Plasma protein binding should be < 99 %a nd there should be little or no inhibition or induction of cytochrome p450'sw ith no mutagenico rt eratogenic indications (safety pharmacology) * To xicology should show no adversec ardiovascular effects (the importanti on channel for cardiac arrhythmia hERG is assayed) and there should be no CNS side-effects at am ultiple of at least 20 timest he anticipated human dose (off-target CNS receptors and transporters such as DAT, SERTetc. are assayed). No DEREK toxicology alerts (these are warnings on possible toxicity using the DEREK software available from LhasaL td) [2] * Ames test negative (mutagenicity) * There is no evidence of mechanism based toxicity (for the target).
In-vitro and in-vivo assays are chosent oe valuate these parameters( e.g. in-vitro tests include Ames, hERG, bacterial toxicity,p hospholipidosis etc. and are available from CRO's. Relevant in-vivo models of PAHa re also available such as the monocrotiliner at, the Sugen rat and the hypobaric mouse). [3] Of course, additional constraints are added as development of the program ensues e.g. the requirement to show tissue remodelling in ad isease progression model of PAH was seen as beneficial and incorporated into the in-vitro screening using ac ell proliferation assay.Af ull ADMEa nd toxicity package (in two species) of the final lead compoundsw ould generally be required before first exposure in man.
Of interest is that we defined 5-HT2A, ac losely related 5-HT receptor,a sa n" anti-target" -o ne which would be associated with additional potentiallyu ndesirable effects( ef-fects on blood clotting, platelet aggregation, CNS effects), and whichd ue to its similarities to 5-HT1B is also commonly seen to have affinity for 5-HT1B ligands. Also, to validate the "5-HT1B"h ypothesis that this receptor is ak ey component of PAH, we needed to discoverh ighly selective ligands to probe this specific mechanism of the disease process.
The progression from "hit" to lead in this project is shown below.A st he series is optimised, using both pharmacophore and site-directed constraintsf rom homology models and X-ray crystallography,t he progression from al ow affinity (mM) hit to ah igh affinity (nM) selective series can be seen in Figure 1 .
Iw ill focuso nafew aspects of this work:u sing the X-ray structures to optimisea ffinity and efficacy,a nd also the required ADME constraints,p articularly in attemptingt o reduce CNS effects( the molecule should be optimisedt o exhibit peripheral cardiovascular effects while showingn o or limited CNS effects).
Previous work on 5-HTb inding compoundsh as utilised ap harmacophore model developed for the optimisation of agonists,shown below in Figure 2 (distances showninAngstroms). [4] We have strong evidencef rom Structure Activity Relationships (SAR)t hat antagonistso fs imilar structure bind in the same region and take advantage of the same interactions with the protein, therefore this pharmacophore model can be extended to include antagonists.
The big advantage of pharmacophore models is that the medicinal chemist can quickly and easily visualise the fit of new molecule ideas to the geometric constraints. Indeed, this model has been further developed, basedo nS AR to include extension of the original model as additional functional groupsw ere added. This model was subsequently developed to discover 5-HT antagonists. [5] Computational modelling was used at each stage.S ome of the screening approaches used were:
* Pharmacophore constraints were used as the initial design criteria.
SPECIAL ISSUE Figure 1 . The lead optimisation process for novel 5-HT1B antagonists. This shows that the initial simple starting 'hit' and the development of the series as additional substituents are added to improve the affinitya nd other target properties such as selectivity.T his Figure should be read in conjunction with Figure 6 , which may explain in more detail the reasoning behind the compound development. * The novel molecules were docked into the binding site of the receptor using GOLD [6, 7] and the goodness of fit determined from visual analysis and the docking score. * clogD, MR,s olubility,p olar surface area (PSA) were computed. * Compounds were evaluated for CNS penetrationb ased on computational models (see below for an example model) using computed properties. * To xicity was evaluated using DEREK 2 .
* Possible side products of metabolism were evaluated (MetaPrint2D). [8] * Transporter interactions weree valuated using ar eadacross approach( MetraBase). [9] * ADME/toxicity constraintsw ere included (FAF-Drugs2). [10] The antagonist model reducest oaseries of simple rules that can be incorporated into compound design:w eo bserved that ligandsb ased on the 5-HTs tructure but without the complete indole ring were often partial agonists or antagonists.A dding a2 -substituentt ot he indole ring,w ith adjustment of the chain length of the ethylamine (to maintain the appropriate pharmacophore distances and hence affinity) often resulted in antagonists. Replacing the 3-substituted indolew ith a4 -substituted indole-piperazine could result in antagonists. Confirmation of this approach was the ability to reproducibly design 5-HT1B antagonists. A simple example molecule from this series is showni n Figure 3 , the atom-coloured compoundi sa na ntagonist with ab inding affinity of 106 nM at 5-HT1B (human)a nd is compared to the 5-HT1B partial agonistz olmitriptan (binding affinity 19.9 nM). Both molecules are assumed to occupy as imilar bindings ite in the receptor -b ut one is ap artiala gonist and the othera na ntagonist. Indeed, receptor docking of the ligands into 5-HT1B showsv ery similar results to the previously determined pharmacophore overlay.T he overlayw as generatedu sing GASP. [11] The indole is replaced by am ethoxy-phenyl substructure, with the piperazine protonatedn itrogeno verlaying the protonated amine of the dimethylethylamine sidechain of zolmitriptan,w hile the hydrogen-bond acceptor (ketone) overlays with as imilar acceptor in zolmitriptan.N ote the pyrroline of the indole is replacedb yamethoxy group, which, as described above, would be expected to give an antagonist. Indeed,s ubstitutiona tt he 2-position of the indole ring appearedt or esult in antagonists by (from steric-clashes with the receptor)m oving the indoler ing from the 'agonist site' (see the paper "2,5-substituted tryptamine derivatives as vascular 5HT1B/1D receptor antagonists"). [5] From dockinge xperiments, we hypothesised thatt he phenylr ing is involved with p-p stacking interactions with ac omplimentary phenylr ing in the receptor (see Figure4 below: GR43175, an on-selective5 HT1-B antagonist, docked into the receptor model).
Starting from homology models,b ut subsequently utilising the published X-ray structures of5 -HT1B( which became available in 2013, 4IAQ and 4IAR from the protein databank, PDB), [12] the bindings ite is identified as being adjacent to the important residue Asp129 (from mutagenesis studiest houghtt ob ind to the protonateda mine of 5-HT) and inspection of the binding site topology,r emarkably, shows the presence of the expectedc omplimentary pharmacophore( Asp129, Thr355, Phe330), deduced from ligand-based studies. An example of the 5-HT1B binding antagonist GR43175, [13] is shown docked into the bindingsite cavity (using GOLD) in Figure 4 .
To focus on aspects of theu sefulness of the protein structure in optimising affinity and selectivity,t he stepchangei nbindinga ffinity and selectivity between structures [4] to [7] was driven by the realisationt hat there were two available hydrogen-bondings idechains in the 5-HT1B transmembranes equence (Tyr109 and Asp352)t hat were possible beneficial interactions if paired with the 'right' substituents (combining ah ydrophobic and ah ydrogen-bonding region).T his resulted in affinity increasing from 51 nM to 2nM, but more importantly,s electivity against 5-HT2A increasing from 17-fold to 174-fold while decreasing lipophilicity and increasing Polar Surface Area (making CNS penetrationl ess likely). In going from 5-HT1B to 5-HT2A, residues Tyr109 and Asp352 are changed to isoleucinea nd asparagine (sequence alignmentf rom EMBOSSN eedle from EBI). [14] This changes the binding environment and allows optimisation of excellent selectivity for 5-HT1B over 5-HT2A to be obtained. This is shown in Figure 5 .
This trend has continueda st he seriesc ontinues to be optimised. The features of the compound series are shown below in Figure 6 .
Since the objective of this optimisation strategy is, among other factors, to optimise the compounds for pe-SPECIAL ISSUE Figure 3 . Zolmitriptan is overlaid with an ovel 5-HT1B antagonist showing the close proximity of the compatible pharmacophore components. Despite one molecule being ap artial agonist, and the other an antagonist, they occupy similar positions from the docking study.
ripheral cardiovascular effects and lower CNS penetration (or at least to have ah igher probability of showing no CNS effects),asimple modeld eveloped by Clark et al. [15] using ClogP and polar surface area (PSA) can be useful here as an SPECIAL ISSUE Figure 4 . The 5-HT1B X-ray structure (4IAQ), with the binding site for 5-HT highlighted. The binding site is shown in more detail, with the exemplar antagonist compound GR43175 docked. The pharmacophore (from the protein side) which is deduced to interact with GR43175 13 (and zolmitriptan) is shown. Figure 5 . Optimisation of as ubstituent for affinity and selectivity using the homology models and X-ray crystal structures of 5-HT1B. In particular,t his image shows the additional hydrogen-bonding interactions obtained by substitution of the phenyl ring with appropriate fragments. This translates into both higher affinity and selectivity.
example to demonstrate the probability of CNS penetration. This modelw as developed from as et of measured compounds showing ar ange of CNS penetration. One of the published models is shown below.
log BB ¼ À0:0148ð0:001ÞPSA þ 0:152ð0:036ÞClogP þ0:139ð0:073Þ
From the equation, it is obvious that increased polar surface area (PSA) and amore hydrophilic clogP would be predicted to reduce Blood-Brain penetration (BB). An umber of similarm odels could of course be chosen (and more sophisticatedm odels), [16] using ac ombination of the physicochemicalp roperties of the molecules (including the ionisation of the aminea nd other groups (pKa, logD) are of course more appropriate here).
We can therefore computea ne stimate of BB, and incorporate this into our compoundd esign. An example of modifiedc ompoundsf rom this seriesa nd their BB penetration is shown below in Figure7.S everal of the compounds are predicted to have very low predictedB B.
Additionally,w ec an also investigate whether transporters were likely to actively move compoundsa cross the blood brain barriera nd into/out-of the brain. As imple "read-across" (looking for similar structures) can be used to look for similar structures that are transported. Although no very similar compounds were found (in ad atabse of compounds and transporters, MetraBase [9] )w ith aT animoto > 0.4, the closest compound was as ubstratef or MDR1, which in the capillary endothelial cells of the blood-brain barrier pumps from the brain into the capillaries (so this is promising). The amount of available experimental data on transporters is still al imiting factor in producingr eliable models of compound transport. Of course,i nt his shorta rticle, this is just as napshot of some of the constraints applied. Importantly, it can be mentioned that in an experimantal panel of 60 diverse receptors,f or the lead molecules there was only ones ignificant off-target effect (screened at 5 mml ooking for > 90 % inhibition) which is currently being removed by additional compound design. Also,s ome analogs (having ap rotonated-amine combined with ap henyl ring,w hich can be associated with hERG binding)s howed hERG toxicity,b ut again by design these effects have beenremoved. Drugdiscovery is often ac yclic-process of design/screeninga nd re-design to remove unwanted effectsa nd optimise the desired profile. Importantly,in-vivo the compounds have shown significant desirable effects in treatings ymptoms of PAH( which will be published elsewhere). Development of this series continues.
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